Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Sodium oxybate
Drug ID BADD_D02047
Description Sodium oxybate (Xyrem) is a central nervous system depressant used for the treatment of cataplexy and extreme daytime sleepiness (EDS) associated with narcolepsy. It is the sodium salt of gamma hydroxybutyric acid (GHB) which is an endogenous compound and a metabolite of the neurotransmitter GABA. The exact mechanism of action for treating EDS and cataplexy is not known but is is hypothesised that its therapeutic effects are due to GABA(B) effects on noradrenergic, dopaminaergic and thalamocorticol neurons. The drug follows non-linear pharmacokinetics. As it has been associated with misuse/abuse it is strictly controlled and all patients and prescribers must enroll in the sodium oxybate REMs program in order to gain access to the medication.
Indications and Usage For the treatment of cataplexy and excessive daytime sleepiness (EDS) associated with narcolepsy.
Marketing Status approved
ATC Code N01AX11; N07XX04
DrugBank ID DB09072
KEGG ID D05866
MeSH ID D012978
PubChem ID 23663870
TTD Drug ID Not Available
NDC Product Code 13551-001; 49812-0207; 0054-9628; 69238-2391; 0792-4356; 13551-002; 13551-003; 68727-100; 61960-0221; 13551-004; 59116-5950
UNII 7G33012534
Synonyms Sodium Oxybate | Oxybate, Sodium | Sodium Oxybutyrate | Oxybutyrate, Sodium | Sodium gamma-Hydroxybutyrate | Sodium gamma Hydroxybutyrate | 4-Hydroxybutyrate Sodium | 4 Hydroxybutyrate Sodium | Oxybate Sodium | gamma-Hydroxybutyrate | gamma Hydroxybutyrate | Somsanit | Xyrem
Chemical Information
Molecular Formula C4H7NaO3
CAS Registry Number 502-85-2
SMILES C(CC(=O)[O-])CO.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lipoma16.18.01.001; 15.09.01.0010.001046%Not Available
Livedo reticularis24.03.04.003; 23.06.05.0010.000590%Not Available
Logorrhoea19.19.02.001; 17.02.08.0060.001502%Not Available
Loss of consciousness17.02.04.0040.009549%Not Available
Lymphadenopathy01.09.01.0020.002763%Not Available
Macular degeneration06.09.03.0010.000268%Not Available
Malaise08.01.01.0030.063842%
Malignant melanoma23.08.01.001; 16.03.01.0010.000805%Not Available
Mania19.16.02.0020.001127%
Mass08.03.05.0030.000536%Not Available
Melanocytic naevus23.10.01.007; 16.26.01.0070.000268%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.013439%
Meniere's disease17.02.12.003; 04.04.02.003; 07.01.07.0070.000858%Not Available
Menopausal symptoms21.02.02.0020.001046%Not Available
Menstrual disorder21.01.01.0040.001824%Not Available
Mental impairment19.21.02.003; 17.03.03.0020.004319%Not Available
Metabolic alkalosis14.01.02.0040.000590%Not Available
Micturition disorder20.02.02.0050.001046%Not Available
Micturition urgency20.02.02.0060.001636%
Middle insomnia17.15.03.003; 19.02.01.0030.010676%Not Available
Migraine24.03.05.003; 17.14.02.0010.025644%Not Available
Migraine with aura24.03.05.005; 17.14.02.0020.000858%Not Available
Miosis17.02.11.002; 06.05.03.0030.000939%Not Available
Mitral valve incompetence02.07.01.0020.000268%Not Available
Moaning08.01.03.094; 19.04.02.0110.002548%Not Available
Mood altered19.04.02.0070.002629%Not Available
Motion sickness17.02.12.001; 04.04.01.0010.002092%Not Available
Movement disorder17.01.02.0100.002736%Not Available
Multiple allergies10.01.03.0300.003192%Not Available
Muscle atrophy15.05.03.003; 17.05.03.0040.000402%Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 19 Pages